Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H (HK:9989) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has released its unaudited third quarterly report for 2024, confirming the accuracy and completeness of the financial information. The company’s board of directors, including executive and independent non-executive members, approved the report during a recent meeting. Investors should note that the report complies with PRC Accounting Standards and Hong Kong’s listing rules, reflecting Hepalink’s commitment to transparency.
For further insights into HK:9989 stock, check out TipRanks’ Stock Analysis page.